Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by baggerx99 on Sep 13, 2023 12:25pm

IBD News - Q3?

End of Q3 is nearing?
Comment by Harper75 on Sep 13, 2023 12:35pm
They had opportunity to change the timeline with the July update...that made me think they must be confident with only 2months remaining in the Quarter.  
Comment by MrMugsy on Sep 13, 2023 5:59pm
Not IBD but a new molecule was planned to be introduced in Q3. Don't expect it until Q4.
Comment by Harper75 on Sep 14, 2023 12:32pm
Q3 still has some daylight but a delay to Q4 (or later...?) at this point chips away at the remaining confidence I had in the Antibe team.  WTH are we to think if they are unable to meet deadlines updated 60days out.  
Comment by MrMugsy on Sep 15, 2023 12:37am
It isn't about hitting or missing timelines - it's about choosing "when" to release. Lets wait for A before we do B.
Comment by Harper75 on Sep 15, 2023 3:32pm
I agree that strategic  "A vs B" should go into the timeline narrative but I disagree that missing milestones is of no consequence.   Devise the plan...communicate the plan...execute to plan.  I'm old fashioned that way...
Comment by MrMugsy on Sep 17, 2023 11:01am
So am I Harper ... and I agree with you (in general). But we're not making widgets here.  We're dealing with the unknown in drug development - as we learned back in the AME. So if you were to ask me for a schedule in drug development, I'd tell you that you're not getting one. That's not acceptable either. So you're stuck getting what you get ...more  
Comment by Harper75 on Sep 19, 2023 9:01am
Hey Mugsy - thanks for the detailed reply.  Delays are to be expected - no arguments here.  I was calling out any Corporate update should be be able to forecast accuratly 60-90days out with more uncertainty the further out the timeline.   Perhaps I'm overly anxious for the positive new cycle to re-start after riding this wave for too many years.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities